200例斯堪的纳维亚全踝关节置换(STAR)假体的生存率与长期结局:连续病例系列
报告单中心单术者连续200例(184例患者)STAR全踝关节置换的长期临床与影像学结局。32例假体失败(16%),平均翻修时间80个月(2至257个月),15.8年以翻修为终点的假体生存率为76.16%(95%CI 64.41至87.91)。AOFAS后足评分从术前平均28分(10至52分)改善至长期随访时61分(20至90分)。
要点
- 200例STAR假体连续病例中32例失败(16%),平均翻修时间80个月(2至257个月)。
- 15.8年以翻修为终点的假体生存率为76.16%(95%CI 64.41至87.91),研究期间生存率呈稳定但低幅下降。
- AOFAS后足评分从术前平均28分(10至52分)改善至长期随访时61分(20至90分)。
核心结论
- STAR假体长期生存率可为后续新设计踝关节假体提供基准参照。
- 英国STAR假体已大部分被新设计全踝关节置换假体取代,后者可能具有改进的特性与手术技术。
研究设计与样本
- 单中心连续病例系列,1993年11月至2000年2月由单术者植入200例STAR假体(184例患者)。
- 前瞻性收集人口学与临床数据,记录末次可用状态用于生存分析,所有存活患者接受定期临床与影像学复查。
- 疼痛与功能采用美国足踝外科协会(AOFAS)后足评分系统评估。
- 主要终点为假体失败需翻修一个或全部组件,采用Kaplan-Meier法生成生存曲线及95%置信区间,并计算每年失败率。
主要发现
- 研究结束时84例患者(87踝)存活,其中女性45例、男性39例,手术时平均年龄54岁(18至72岁)。
- 存活患者中类风湿关节炎(RA)40踝、骨关节炎(OA)47踝。
- 32例假体失败(16%)需翻修手术,平均翻修时间80个月(2至257个月)。
- 15.8年以翻修为终点的假体生存率为76.16%(95%CI 64.41至87.91),研究期间生存率呈稳定但低幅下降。
- AOFAS评分从术前平均28分(10至52分)改善至长期随访时61分(20至90分)。
关键数值与推荐
- 假体失败定义为需翻修一个或全部组件。
- 15.8年假体生存率76.16%(95%CI 64.41至87.91)。
- 32例假体失败(16%),平均翻修时间80个月(2至257个月)。
- AOFAS评分术前平均28分(10至52分) vs 长期随访平均61分(20至90分)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: We report the long-term clinical and radiological outcomes of a consecutive series of 200 total ankle arthroplasties (TAAs, 184 patients) at a single centre using the Scandinavian Total Ankle Replacement (STAR) implants. PATIENTS AND METHODS: Between November 1993 and February 2000, 200 consecutive STAR prostheses were implanted in 184 patients by a single surgeon. Demographic and clinical data were collected prospectively and the last available status was recorded for further survival analysis. All surviving patients underwent regular clinical and radiological review. Pain and function were assessed using the American Orthopaedic Foot and Ankle Society (AOFAS) hindfoot scoring system. The principal endpoint of the study was failure of the implant requiring revision of one or all of the components. Kaplan-Meier survival curves were generated with 95% confidence intervals and the rate of failure calculated for each year. RESULTS: A total of 84 patients (87 ankles) were alive by the end of this study. Of the surviving 84 patients (87 ankles; rheumatoid arthritis (RA), n = 40; OA, n = 47), 45 were women and 39 were men, with a mean age of 54 years (18 to 72 years) at the time of surgery. A total of 32 implants failed (16%), requiring revision surgery. The mean time to revision was 80 months (2 to 257). The implant survival at 15.8 years, using revision as an endpoint, was 76.16% (95% confidence interval (CI) 64.41 to 87.91). We found a steady but low decrease in survival over the study period. The mean AOFAS score improved from 28 (10 to 52) preoperatively to 61 (20 to 90) at long-term follow-up. CONCLUSION: STAR prostheses in the United Kingdom have now been largely superseded by newer design TAAs, potentially with improved characteristics and surgical techniques. The long-term survivorship for the STAR prosthesis can provide a benchmark for these later designs of ankle arthroplasty.
引用
- Clough T, Bodo K, Majeed H, et al. Survivorship and long-term outcome of a consecutive series of 200 Scandinavian Total Ankle Replacement (STAR) implants. Bone Joint J. 2019. PMID: 30601052. doi:10.1302/0301-620X.101B1.BJJ-2018-0801.R1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。